General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-05-12 | 2023-03 | 0 | N/A | N/A | N/A |
2022-05-13 | 2022-03 | 0 | N/A | N/A | N/A |
2022-02-14 | 2021-12 | 0 | N/A | N/A | N/A |
2021-05-17 | 2021-03 | 0 | N/A | N/A | N/A |
2020-05-11 | 2020-03 | 0 | N/A | N/A | N/A |
2019-11-13 | 2019-09 | 0 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-01-09 | GRONFELDT-SORENSEN HENRIK | Director | 0.00 | Purchase |
2022-05-17 | GUMRUKCU SERHAT | Beneficial Owner of more than 10% of a Class of Security | 16.99M | Sale |
2018-05-23 | LEIRE ERIC JEAN MARIE | Chief Executive Officer | 73.25K | Purchase |
2021-12-15 | PUCHE LUISA | Chief Financial Officer | 16.27K | Stock Award(Grant) |
2022-03-21 | SANDLER CARL FOREST JR | Director and Beneficial Owner of more than 10% of a Class of Security | 8.42M | Sale |
2023-06-25 | SINDLEV RENE | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Blackrock Inc. | 1.23M | 652.95K | 2.11% |
2023-03-30 | Vanguard Group, Inc. (The) | 322.28K | 170.81K | 0.55% |
2023-03-30 | Geode Capital Management, LLC | 318.86K | 168.99K | 0.55% |
2023-03-30 | State Street Corporation | 307.41K | 162.93K | 0.53% |
2023-03-30 | Northern Trust Corporation | 163.55K | 86.68K | 0.28% |
2023-03-30 | Nuveen Asset Management, LLC | 121.51K | 64.40K | 0.21% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Vanguard Total Stock Market Index Fund | 416.68K | 220.84K | 1.07% |
2023-02-27 | iShares Russell 2000 ETF | 350.38K | 185.70K | 0.90% |
2022-12-30 | Vanguard Extended Market Index Fund | 222.70K | 118.03K | 0.57% |
2023-02-27 | iShares Russell 2000 Value ETF | 202.52K | 107.33K | 0.52% |
2023-01-30 | Fidelity Small Cap Index Fund | 145.29K | 77.00K | 0.37% |
2023-01-30 | TIAA-CREF Funds-Equity Index Fund | 93.46K | 49.53K | 0.24% |
It’s fucken lunch hour man!
On March 24, 2021, the Enochian Biosciences and SRI announced achieving complete remission for 15 months, in a 36years old patient with recurrent glioblastoma. important findings were published today, in the peer-reviewed American Journal of Case.
It is very rare, in fact, impossible to achieve complete remission for this highly aggressive and deadly form of brain cancer.
Go above that 4 and we will see 6 pretty soon.